

# UCLA

## UCLA Previously Published Works

### Title

Transcriptome Profiling of Peripheral Blood in 22q11.2 Deletion Syndrome Reveals Functional Pathways Related to Psychosis and Autism Spectrum Disorder

### Permalink

<https://escholarship.org/uc/item/8bd9d0wf>

### Journal

PLOS ONE, 10(7)

### ISSN

1932-6203

### Authors

Jalbrzikowski, Maria  
Lazaro, Maria T  
Gao, Fuying  
[et al.](#)

### Publication Date

2015

### DOI

10.1371/journal.pone.0132542

Peer reviewed

RESEARCH ARTICLE

# Transcriptome Profiling of Peripheral Blood in 22q11.2 Deletion Syndrome Reveals Functional Pathways Related to Psychosis and Autism Spectrum Disorder

Maria Jalbrzikowski<sup>1</sup>, Maria T. Lazaro<sup>2</sup>, Fuying Gao<sup>1</sup>, Alden Huang<sup>2</sup>, Carolyn Chow<sup>1</sup>, Daniel H. Geschwind<sup>1,3</sup>, Giovanni Coppola<sup>1,3</sup>, Carrie E. Bearden<sup>1,4</sup>\*

**1** Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, United States of America, **2** Interdepartmental Neuroscience Program, University of California Los Angeles, Los Angeles, United States of America, **3** Department of Neurology, University of California Los Angeles, Los Angeles, United States of America, **4** Department of Psychology, University of California Los Angeles, Los Angeles, United States of America

☞ These authors contributed equally to this work.

\* [cbearden@mednet.ucla.edu](mailto:cbearden@mednet.ucla.edu)



**OPEN ACCESS**

**Citation:** Jalbrzikowski M, Lazaro MT, Gao F, Huang A, Chow C, Geschwind DH, et al. (2015) Transcriptome Profiling of Peripheral Blood in 22q11.2 Deletion Syndrome Reveals Functional Pathways Related to Psychosis and Autism Spectrum Disorder. *PLoS ONE* 10(7): e0132542. doi:10.1371/journal.pone.0132542

**Editor:** Therese van Amelsvoort, Maastricht University, NETHERLANDS

**Received:** December 23, 2014

**Accepted:** June 17, 2015

**Published:** July 22, 2015

**Copyright:** © 2015 Jalbrzikowski et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data are freely available from the Gene Expression Omnibus (GEO) repository from NIH. Accession number: GSE59216.

**Funding:** The authors would like to acknowledge the following funding sources: 5P50 HD055784 ACE Center (Daniel H. Geschwind), P30 NS06269 National Institute of Neurological Disorders and Stroke (NINDS) Informatics Center for Neurogenetics and Neurogenomics (Giovanni Coppola), R01MH085953 Neurodevelopment and Psychosis in the 22q11.2 Deletion Syndrome (Carrie E. Bearden),

## Abstract

### Background

22q11.2 Deletion Syndrome (22q11DS) represents one of the greatest known genetic risk factors for the development of psychotic illness, and is also associated with high rates of autistic spectrum disorders (ASD) in childhood. We performed integrated genomic analyses of 22q11DS to identify genes and pathways related to specific phenotypes.

### Methods

We used a high-resolution aCGH array to precisely characterize deletion breakpoints. Using peripheral blood, we examined differential expression (DE) and networks of co-expressed genes related to phenotypic variation within 22q11DS patients. Whole-genome transcriptional profiling was performed using Illumina Human HT-12 microarrays. Data mining techniques were used to validate our results against independent samples of both peripheral blood and brain tissue from idiopathic psychosis and ASD cases.

### Results

Eighty-five percent of 22q11DS individuals (N = 39) carried the typical 3 Mb deletion, with significant variability in deletion characteristics in the remainder of the sample (N = 7). DE analysis and weighted gene co-expression network analysis (WGCNA) identified expression changes related to psychotic symptoms in patients, including a module of co-expressed genes which was associated with psychosis in 22q11DS and involved in pathways associated with transcriptional regulation. This module was enriched for brain-expressed genes, was not related to antipsychotic medication use, and significantly

T32NS048004 NINDS Training Grant (Maria Jalbrzikowski), Heyler Research Award (Maria Jalbrzikowski), and NSF-GRFP DGE-0707424 National Science Foundation (NSF) Graduate Research Fellowship Program (Maria T. Lazaro). Dr. Bearden had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to and have approved the final manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

overlapped with transcriptional changes in idiopathic schizophrenia. In 22q11DS-ASD, both DE and WGCNA analyses implicated dysregulation of immune response pathways. The ASD-associated module showed significant overlap with genes previously associated with idiopathic ASD.

## Conclusion

These findings further support the use of peripheral tissue in the study of major mutational models of diseases affecting the brain, and point towards specific pathways dysregulated in 22q11DS carriers with psychosis and ASD.

## Introduction

Identification of replicable risk genes for developmental neuropsychiatric disorders such as autism and schizophrenia has been hampered by the substantial complexity and heterogeneity of these disorders. Although the majority of cases are of unknown etiology (idiopathic), increasing evidence suggests that rare copy number variants have robust and reproducible impacts on disease risk [1–3]. Investigation of highly penetrant genetic subtypes of these disorders offers a complementary strategy that may elucidate more homogeneous biological pathways [4,5]. The 22q11.2 Microdeletion Syndrome (Velocardiofacial/DiGeorge syndrome; OMIM #192430; 22q11DS) is a particularly compelling model, as it represents one of the most common known recurrent genetic risk factors for the development of these disorders [6]. Multiple studies have found that 23–41% of adolescents and adults with 22q11DS meet criteria for a psychotic disorder [7–13]. Furthermore, 14–50% meet criteria for an autism spectrum disorder (ASD) in childhood [14–17]. Genes within the 22q11.2 locus have been implicated in the etiology of idiopathic psychosis and ASD, providing support for the notion that genes within this region may make a broader contribution to disease susceptibility and/or associated intermediate phenotypes [18–24].

In addition to the elevated rates of psychotic disorder and ASD seen in 22q11DS, there are a diverse range of neuropsychiatric conditions observed in this population, including attention-deficit/hyperactivity disorder (ADHD), anxiety disorders, and mood disorders [7,13]. In fact, at any age, 60% of individuals with 22q11DS meet criteria for a psychiatric disorder of some kind [7,12,13,25] and it is common for an individual with 22q11DS to meet criteria for multiple psychiatric diagnoses concurrently [26]. However, the schizophrenia phenotype in 22q11DS is the most specific psychiatric phenotype identified, as it is the only psychiatric disorder found at a greater rate in 22q11DS than in other neurodevelopmental disorders [6,27]. While idiopathic forms of ASD and schizophrenia are both characterized by social cognitive deficits [28] and abnormalities in associated neural circuitry [29], preliminary data in 22q11DS suggests that schizophrenia and ASD are two distinct phenotypes in 22q11DS, as ASD symptoms in childhood did not predict psychosis in adulthood [30]. Thus, a logical next step would be to interrogate these two phenotypes further in 22q11DS, to explore whether gene expression profiles differ amongst these two conditions and possibly identify genes uniquely associated with each disorder.

All 22q11DS patients share a 1.5 Mb deletion at the 22q11.2 locus, encompassing approximately 28 genes; in 85% of the carriers the deletion spans 3 Mb, including 90 known genes [31]. Several CNS-relevant genes are encoded in the 1.5 Mb critical region, including genes involved in neuronal migration, myelination and brain development [32,33]. This region is

flanked by proximal and distal low-copy-number repeats (LCRs) or segmental duplications, making this region vulnerable to errors in chromosomal recombination [34,35]. Two previous studies using high-resolution comparative genomic hybridization (aCGH) arrays showed significant breakpoint variability within these LCRs in 22q11DS individuals, suggesting that variability of deletion breakpoints may contribute to the variable clinical presentation observed in 22q11DS [36,37]; however, the pathogenetic mechanisms underlying the development of neuropsychiatric disorders in 22q11DS have yet to be elucidated.

The sole prior publication to date to examine blood-based gene expression profiles in 22q11DS confirmed significantly reduced expression of genes within the 22q11.2 locus in 22q11DS patients relative to controls, and found that a number of functional pathways, including some previously associated with idiopathic schizophrenia, were involved [38]. However, due its small sample size ( $N = 16$ ) the study was unable to evaluate differential expression related to phenotypic variability in 22q11DS.

Additionally, multiple testing presents a challenge for expression microarray studies, which test thousands of transcripts simultaneously. Gene co-expression network analysis offers an alternative approach, allowing the identification of groups of functionally related genes or 'modules', whose expression patterns are highly correlated. These modules can then be compared between cases and controls, and analyzed in relation to both categorical and quantitative phenotypes [39,40].

To better characterize how the 22q11DS genotype gives rise to such varied phenotypes, we sought to answer the following questions: 1) Is there variation in deletion breakpoints in 22q11DS?; 2) are there differences in gene expression between 22q11DS patients and controls?; 3) are there networks of co-expressed genes associated with psychotic illness or ASD diagnosis in 22q11DS?;, and 4) can we validate our results against published datasets available from other samples of both peripheral blood and brain tissue from idiopathic psychosis and ASD cases?

## Methods and Materials

### Subjects

Forty-six patients with a molecularly confirmed diagnosis of a 22q11.2 deletion and 66 unaffected healthy controls were recruited from an ongoing longitudinal study at the University of California, Los Angeles. 22q11DS participants were recruited from posts to 22q11DS/Velocardiofacial online foundations and flyers through contacts with local craniofacial or genetics clinics. Controls were recruited from flyers posted at local schools and community centers. Demographic information is reported in [Table 1](#). Psychotropic medication usage for 22q11DS participants is reported in [S1 Table](#).

This study was approved by the UCLA Institutional Review Board and performed in accordance with the Declaration of Helsinki. All subjects or their legal guardians provided written informed consent, after study procedures were fully explained.

### Whole-genome Microarrays

RNA was extracted from whole blood using the PAXgene extraction kit (Qiagen), then stored at  $-80^{\circ}\text{C}$  for subsequent analysis. RNA quantity was assessed with Nanodrop (Nanodrop Technologies) and quality with the Agilent Bioanalyzer (Agilent Technologies). Whole-genome transcriptional profiling was performed using Illumina Human HT-12 microarrays. 200 ng of total RNA were amplified, biotinylated and hybridized to Illumina Human V4-HT-12 Beadchips, including approximately 47,000 probes, following the manufacturer's recommendations. Slides were scanned using Illumina BeadStation, and the signal was extracted by using Illumina BeadStudio software.

**Table 1. Demographic information for 22q11DS participants and controls.**

	22qDS (N = 46)	Unrelated Controls (N = 24)	Family Member Controls (N = 42)	p-value
Age (+/-SD)	17.3 (11.9)	15.4 (5.2)	41.7 (12.9)	$p < .001$
Gender (N, % female)	23 (50%)	8 (33%)	14 (33%)	$p = .21$
Psychotic Disorder	6 (13%)	NA	NA	
Autism Spectrum Disorder	16 (40%) <sup>a,b</sup>	NA	NA	
WASI IQ (mean, +/-SD)	76.6 (13.4) <sup>c</sup>	112.3 (20.9) <sup>d</sup>	NA	$p < .001$
SRS T Score (mean, +/-SD)	69.7 (16.0)	52.7 (14.8)	NA	$p < .001$

<sup>a</sup>assessed in 40 participants

<sup>b</sup>3 22q11DS participants had comorbid diagnoses of ASD and psychotic disorder

<sup>c</sup>assessed in 43 participants

<sup>d</sup>assessed in 23 participants.

doi:10.1371/journal.pone.0132542.t001

## Comparative Genomic Hybridization Arrays

To characterize the boundaries of the 22q11.2 deletion, we used a custom NimbleGen 12\*135 HX12 array (see [S1 Text](#)).

## Outcome Measurements

Master's or PhD-level clinicians conducted all assessments. Prior to conducting diagnostic interviews, clinicians had to achieve good to excellent reliability with a set of gold standard ratings (kappa coefficients of .90 or greater for categorical diagnoses and intra-class correlations coefficients (ICC's) ranging from 0.85 to 1.00 for quantitative symptom ratings).

For all participants, DSM-IV psychotic disorder diagnosis was determined through a parental interview using the Computerized Diagnostic Interview Schedule for Children (C-DISC, [41] 6–9 years) and/or the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) [42,43], with an additional developmental disorders module, administered to the proband and parent (10 years and up). 22q11DS participants were also administered the SIPS/Scale of Prodromal Syndromes (SOPS), a dimensional measure of psychotic symptom severity, including sub-threshold (prodromal) and fully psychotic symptoms [44]. Symptoms on this scale are rated from 0–6, with zero representing an absence of symptoms and six referring to a severe and psychotic level of symptoms. Diagnostic formulations and SIPS symptom ratings for all cases were additionally reviewed in consensus diagnosis meetings led by the study director, a board-certified psychologist (CEB).

Diagnoses of autism and/or ASD were determined using the Autism Diagnostic Observation Schedule (ADOS)[45], administered to the child, and the Autism Diagnostic Interview-Revised (ADI-R)[46], administered to the subject's parent/primary caretaker. Participants were classified as having ASD, based on the ADI-R, if scores were above threshold for the Reciprocal Social Interaction domain, as well as either Communication Impairment or Repetitive Behaviors and Stereotyped Patterns. Scores from the ADOS and ADI-R were used to determine a consensus diagnosis of ASD, as described in a prior publication [47]. Seven subjects in the 22q11DS group were over the age of 18 and thus were not administered the ADI-R/ ADOS; these subjects and their parents/primary caretakers were administered a SCID interview, with an additional developmental disorders module as described above, in order to determine ASD diagnostic status according to DSM-IV diagnostic criteria. Six adult 22q11DS patients (ages 34–61) did not receive the additional developmental disorders module; thus, they were omitted

from the ASD analyses due to the difficulty of making such a diagnosis retrospectively, in the absence of parental information.

## Statistical Analyses

**Microarray-based gene expression analysis.** Raw data were analyzed by using Bioconductor packages in the R statistical environment as previously described. [48] Only samples with an RNA integrity number (RIN) of 7 or greater were included in the analyses [49]. Quality assessment was performed by examining the inter-array Pearson correlation and clustering based on the top variant genes was assessed. We directly removed batch effects using ComBat, which is part of the Bioconductor package in R [46]. Prior to running any analyses, we corrected for age by using a linear model to regress out the participant's age from each transcript and calculate a residual value.

We then performed the following contrast analyses separately: 1) Controls vs. 22q11DS, 2) 22q11Ds-PSY+ vs 22q11DS-PSY-, and 3) 22q11DS-ASD = vs 22q11DS-ASD-. Analyses of 22q11DS-PSY+ vs. controls and 22q11Ds-PSY- vs. controls are reported in the Supplementary Text. Contrast analysis of differential expression was performed by using the LIMMA package [50]. After linear model fitting, a Bayesian estimate of differential expression was calculated. Similar to previous publications examining differential gene expression [51], transcripts were considered significantly DE at  $p < .005$  (uncorrected).

Similar to previous publications which have investigated the statistical significance of the overlap between gene lists [51,52], we then conducted hypergeometric distribution tests [53] using the `phyper` function in R to determine whether the DE transcripts were significantly enriched for brain-expressed genes. This method tests for significance of over-representation of genes within two comparative samples. Unique gene transcripts examined (28,503) were considered the background list. We identified the overlap between unique names of genes identified as brain-expressed [42] and the DE genes obtained from each of our contrasts and calculated the probability of drawing randomly drawing this many overlapping genes from the background list. For DE genes identified in the 22q11DS vs. control contrast, we also conducted a hypergeometric distribution test to identify whether genes in the TDR were over-represented. Bonferroni correction was used to correct for multiple comparisons ( $N = 4$ ;  $p = .013$ ).

For these analyses, Gene ontology (GO) annotation was performed using DAVID (<http://david.abcc.ncifcrf.gov/>) and terms that remained significant after correction for False Discovery Rate ( $q \leq .05$ ) [54] were considered relevant to the analysis of interest. Pathway analysis was performed using the Functional Analysis Annotation tool in the Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, [www.ingenuity.com](http://www.ingenuity.com)). IPA uses literature-based data (scientific publications) to detect over-representation of biologically relevant networks and canonical pathways within the respective set of genes. The algorithm used to determine gene networks and pathways is described in detail in Calvano et al., 2005 [55] and at the following web link: [www.ingenuity.com/wp-content/themes/ingenuitytheme/pdf/ipa/IPA-netgen-algorithm-whitepaper.pdf](http://www.ingenuity.com/wp-content/themes/ingenuitytheme/pdf/ipa/IPA-netgen-algorithm-whitepaper.pdf). Once networks are assigned, a right-tailed Fisher's exact test is used to calculate a  $p$ -value that determines the probability that the biological functions/terms assigned to that network was due to chance. A score is computed for each network ( $-\log_{10}$  of the  $p$ -value). A score of 2 ( $p$ -value = .01) indicates that there is a 1 in 100 chance that the genes found together in the identified network occur due to random chance. Thus, scores greater than 2 have at least 99% confidence of not being due to random chance. For all analyses, we report on the top network identified. Microarray data have been deposited in the NCBI Gene Expression Omnibus database ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo), Accession number: GSE59216).

**Analysis of Age Effects.** In order to identify age-related transcripts, Pearson correlations were used to examine the relationship between gene expression levels with age in both 22q11DS patients and controls.

**Secondary Gene Expression Analyses.** Since a subset of our controls were biological relatives of 22q11DS patients, we conducted a secondary DE analysis comparing 22q11DS patients vs. their unaffected family members in a paired design. To ensure that age differences and relationships between patients and their unaffected relatives were not driving our results, we re-ran the DE analysis including only a subset of age-matched, unrelated controls ( $N = 39$ ) from our overall control sample. To ensure that possible confounding factors, such as RNA Integrity Number and gender, were not affecting our analyses, we re-ran the DE analysis after covarying for these factors. We then separately calculated Pearson correlations between the fold change scores in the original DE analysis and the fold change scores obtained in these separate analyses.

**Weighted Gene Co-expression Network Analysis (WGCNA).** We conducted WGCNA, a systems biology approach used to identify networks of co-expressed genes in relation to phenotypic data [56], using R software [39,40]. Correlation coefficients were constructed between expression levels of genes, and a connectivity measure (topological overlap) was calculated for each gene by summing the connection strength with other genes. Genes were then clustered based on their topological overlap, and groups of co-expressed genes (modules) were identified. Each module is assigned a color, and the first principal component (eigengene) of a module is extracted from the module and considered to be representative of the gene expression profiles in a module. The phenotypic trait of interest is then regressed on the eigengene to determine whether there is a significant relationship between the module and the trait. Phenotypic traits examined within 22q11DS participants included: categorical and dimensional indicators of psychosis (i.e. psychosis diagnosis and total SIPS positive symptoms), ASD, IQ, and gender. Age was not included as a phenotypic trait as it was regressed out prior to conducting WGCNA analyses. For modules that showed a statistically significant relationship with a phenotypic trait of interest ( $p < .05$ , uncorrected), GO analyses and IPA were conducted. We chose to examine modules with a significant association of  $p < .05$  since this was the first investigation linking gene expression modules to clinical phenotypes in 22q11DS. For a more detailed explanation of the WGCNA analysis, see [S1 Text](#). R code used to conduct the analysis can be found in the Supporting Information.

Because 3 of our 22q11DS participants had co-morbid diagnoses of ASD and psychosis, we conducted a post-hoc WGCNA module preservation analysis, examining whether our gene expression modules were preserved in the remaining dataset. We re-ran the WGCNA analysis, using the module assignment of the original dataset. To determine whether the original modules remained preserved when these samples were omitted, we calculated a module preservation Z statistic with modulePreservation function of the WGCNA R Library [40,57]. A Z-statistic greater than 5 reflects significant module preservation in the second dataset.

**Validation with published datasets.** To validate our gene expression and WGCNA results, we conducted hypergeometric probability tests (phyper function in R) between our results and publicly available datasets related to idiopathic psychosis [58] and ASD [59]. Using gene lists obtained from the two DE analyses (22q11DS patients with psychosis (22q11DS-PSY+) versus those without a psychotic disorder diagnosis (22q11DS-PSY-), 22q11DS patients with (22q11DS-ASD+) versus those without an ASD diagnosis (22q11DS-ASD-)), we ran separate hypergeometric tests to determine whether there was enrichment of genes associated with idiopathic psychosis and ASD in each analysis, respectively. Additionally, using gene lists obtained from the psychosis and ASD WGCNA modules, we ran separate hypergeometric tests to determine whether these modules showed enrichment of genes associated with idiopathic

psychosis and ASD, respectively. We also ran hypergeometric tests between the DE genes and genes identified as brain-expressed [42], as well as between the psychosis and ASD gene module lists and brain-expressed genes [42], to test for enrichment of brain-expressed genes. Bonferroni correction was used to correct for multiple comparisons ( $N = 9$ ;  $p = .006$ ).

## Results

### CGH analysis

Inspection of the intensity plots yielded four distinct subgroups of deletion events in our cohort (Fig 1). Fig 1A shows a characteristic aCGH intensity plot for a first-degree relative. The most frequent aberration observed was the 3MB typical deletion region spanning chr21:18.8–21.5 ( $N = 37$ ; 80%, Fig 1B). Two individuals (4%) with the 3 MB deletion carried an additional copy-number gain in the region distal to the 3 MB typically deleted region (TDR), which contains the *TOP3B* gene (Fig 1C). Three individuals (7%) carried a 2.8 MB deletion (Fig 1D), three had a 1.5 MB deletion (Fig 1E), and one had a 1.3 MB deletion (Fig 1F). These deletion types have been described previously in the literature [36,60]; however, to our knowledge the copy number gain containing *TOP3B* has not been previously reported. In four individuals (3 with the 2.8 MB deletion and one with the 1.3 MB deletion) the proximal breakpoint was located ~100kb distally from the start of the TDR. Two annotated coding genes, *DGCR6* and *PRODH*, are present in a normal diploid state among these affected individuals.

### Gene Expression Analyses


**22q11DS vs. Controls.** Four hundred probes were DE in 22q11DS vs. controls ( $p < .005$ , Fig 2A, S2 Table). We observed a significant over-representation of down-regulated probes within the 22q11.2 locus, accounting for 13% of down-regulated genes in 22q11DS ( $p < .0006$ ); however, there was significant variability in expression levels of these genes (S1 Fig). Sixty-five percent of DE genes were brain-expressed [42] ( $p < .00005$ ). GO analyses revealed that the top categories ( $q \leq .05$ ) associated with the DE probes in 22q11DS included regulation of neuronal action potentials, myelination, and axon ensheathment of neurons (Fig 2B). IPA revealed a top network associated with cellular development, and cellular growth and proliferation (Fig 2D). The top canonical pathway associated with this network was axon guidance signaling, with the majority of DE genes down-regulated in 22q11DS patients.

When we removed the genes spanning the 22q11.2 region and re-ran these analyses, our results remained very similar. Eighteen of the 19 reported GO terms overlapped with our original analysis, indicating that the significant GO results were not driven by haploinsufficient genes within the 22q11.2 locus. In addition, three more GO terms were also found to be significant in this second analysis: immune response, regulation phosphate metabolic process, and regulation of epithelial to mesenchymal transition. IPA analyses without the genes spanning the 22q11.2 region showed that the identified top network was still associated with cellular development, and cellular growth and proliferation.

We also conducted secondary analyses comparing 22q11DS-PSY+ vs. controls and 22q11DS-PSY- vs. controls, which can be found in Supporting Information.

**Psychosis.** Thirteen percent (6/46) of 22q11DS patients had a psychotic disorder diagnosis. 141 probes were significantly DE in 22q11DS-PSY+ relative to 22q11DS-PSY- (Fig 3D and 3F, S3 Table), 51% of which were brain expressed (hypergeometric test,  $p = .44$ ). GO analyses ( $q \leq .05$ ) revealed an over-representation of genes associated with mitochondrial organization and transport (Fig 3E). Pathway analyses revealed that the top network of these DE genes was associated with embryonic development and cellular assembly and organization (S2 Fig).






**Fig 1. Representative examples of array comparative genomic hybridization (aCGH) using the NimbleGen 12\*135 HX12 array, from: A) first-degree relatives of 22q11DS patients (N = 11), B) 22q11DS participant with typical 3 Mb deletion (N = 37); C) 22q11DS participant with 3 Mb deletion and distal duplication, which includes the TOP3B gene (N = 2); D) 22q11DS participant with 2.8 MB deletion (N = 3); E) 22q11DS participant with 1.5 MB deletion (N = 3); and F) 22q11DS participant with 1.3 MB Deletion (N = 1).**

doi:10.1371/journal.pone.0132542.g001

**Autism Spectrum Disorder.** Comparing gene expression profiles of 22q11DS patients with (N = 16) and without (N = 24) an ASD diagnosis, we identified 131 DE probes in 22q11DS-ASD+ relative to 22q11DS-ASD- (Fig 3A & 3C, S4 Table). Forty-five percent of DE genes were considered to be brain expressed [42] (hypergeometric test,  $p = .56$ ). The top GO category ( $q \leq .05$ ) associated with the DE genes was cell morphogenesis involved in differentiation (Fig 3B). The top IPA network associated with DE genes in 22q11DS-ASD+ was related to immune response (S3 Fig).

For both DE analyses of psychosis and ASD diagnoses within 22q11DS, none of the DE probes were within the 22q11.2 locus and none of these probes overlapped with the DE genes in the overall (22q11DS vs. control) analysis.



**Fig 2. Differential expression (DE) analysis comparing controls to 22q11DS patients.** A) Number of DE genes at  $p < 0.005$ . Four hundred probes (245 down-regulated, 155 up-regulated) were DE in 22q11DS vs. controls. B) Gene ontology analysis ( $q \leq .05$ ) of DE genes in 22q11DS vs. controls. Top categories included ensheathment of neurons, and regulation of cellular proliferation, signal transduction, and cell communication. Bars represent  $-\log$  of the over-representation  $q$ -value. Red and green represent the proportion of up and down-regulated genes, respectively. C) Heat map depicting fold changes in peripheral blood samples for each 22q11DS participant. Genes are in rows and samples are in columns. Shades of red indicate up-regulation compared to the control condition, shades of green indicate down-regulation. D) Ingenuity pathway analysis results of a top network associated with significantly DE genes ( $p < .005$ ) in 22q11DS vs. controls. This network is associated with cellular development, and cellular growth and proliferation. According to IPA, 10 different molecules in this network are associated with axon guidance signaling, including genes *MTORC1*, *GNB1L* and *PDGFA*, which were all down-regulated in 22q11DS patients.


doi:10.1371/journal.pone.0132542.g002

**Age Relationships.** Age effects on gene expression profiles were consistent with those previously documented in other tissue types (S1 Text, S4 Fig).

**Results from Secondary Gene Expression Analyses.** Results remained similar when the DE analyses were re-run on subsets of 22q11DS and control participants (S1 Text). Specifically, we found highly significant fold change correlation coefficients between results from our overall analyses and those for 22q11DS vs. unaffected relatives only, 22q11DS vs. age-matched controls only ( $r = 0.975$  and  $r = 0.91$ , respectively).

### Weighted Gene Co-Expression Analysis

Hierarchical clustering based on topological overlap identified 24 groups of co-expressed genes, or modules (Fig 4A), each comprising between 45 and 1195 genes. Modules identified



**Fig 3. Differential expression (DE) analysis comparing phenotypic expression (i.e., psychosis, autism spectrum disorders) within the 22q11DS sample.** A. Number of DE genes at  $p < 0.005$  for 22q11DS participants with ASD ( $N = 16$ ) vs. 22q11DS without ASD ( $N = 34$ ). One hundred thirty one probes (54 down-regulated, 77 up-regulated) were DE in 22q11DS patients with ASD in comparison to 22q11DS patients without ASD. B) Gene ontology analysis ( $q \leq .05$ ) of DE genes in 22q11DS with ASD vs. 22q11DS without ASD. The top category was associated with cell morphogenesis involved in differentiation. Bars represent the  $-\text{Log}$  of the over-representation  $q$ -value, as calculated by the DAVID algorithm (<http://david.abcc.ncifcrf.gov/>). Red and green represent the proportion of up and down-regulated genes, respectively. C) Heatmap depicting fold changes in peripheral blood samples for each 22q11DS participant with ASD. Genes are in rows, and samples are in columns. Shades of red indicate up-regulation compared to the 22q11DS participants without ASD, shades of green indicate down-regulation. D) Number of DE genes at  $p < 0.005$  for 22q11DS with a psychotic disorder ( $N = 6$ ) vs. 22q11DS participants without a psychotic disorder ( $N = 40$ ). One hundred forty one probes (62 down-regulated, 79 up-regulated) were DE in 22q11DS with psychosis in comparison to 22q11DS patients without psychosis. E) Gene ontology analysis ( $q \leq .05$ ) of DE genes in 22q11DS with psychosis vs. 22q11DS without psychosis. Top categories were associated with mitochondrial transport and organization. Bars represent the  $-\text{Log}$  of the over-representation  $q$ -value. Red and green represent the proportion of up and down-regulated genes, respectively. F) Heat map depicting fold changes in peripheral blood samples for each 22q11DS participant with psychosis. Genes are in rows, and samples are in columns. Shades of red indicate up-regulation compared to the 22q11DS participants without psychosis, shades of green indicate down-regulation.


doi:10.1371/journal.pone.0132542.g003

and the significance values of their relationship with the phenotypic traits of interest are shown in Fig 4B.


**Psychosis.** We identified one WGCNA module (Purple, 237 probes; Fig 5A, S5 Table) that was associated with psychosis, using both categorical (diagnosis status,  $r = .32$ ,  $p = .03$ ) and dimensional measures of psychotic symptomatology (total SIPS positive symptoms,  $r = .54$ ,  $p = 1.0e-4$ ). Genes co-expressed within this module were predominantly up-regulated in 22q11DS-PSY+, and in 22q11DS subjects with greater positive symptom severity. This module was not associated with antipsychotic medication use ( $r = .04$ ,  $p = .80$ ). Seventy-five percent of the probes in this module were brain-expressed (hypergeometric test,  $p = 1.92e-19$ ) [42]. GO categories ( $q \leq .05$ ) associated with this module were related to protein folding, acetyl-co metabolic processes, and aerobic respiration (Fig A in S5 Fig). Pathway analyses revealed that the top network associated with this module was RNA post-transcriptional modification (Fig B in S5 Fig).

**Autism Spectrum Disorder.** One WGCNA module (Royal Blue, 86 probes, Fig 5B, S6 Table) was associated with ASD diagnosis in 22q11DS ( $r = 0.4$ ,  $p = 0.006$ ). Genes in this module were predominantly up-regulated in 22q11DS-ASD+, and were primarily related to

### A Gene Dendrogram and Module Colors



### B Module–Trait Relationships



**Fig 4. Network construction of co-expressed genes in relation to psychosis and autism spectrum disorders in 22q11DS.** A) Dendrogram of modules identified through Weighted Gene Co-expression Analysis, created through linkage hierarchical clustering of genes. B) Module-Trait relationships for age, gender, psychotic disorder diagnosis, autism spectrum disorder diagnosis, and positive symptoms, as measured by the SIPs. Numbers shown represent Pearson correlations between the modules and traits. P-values are in parentheses. Numbers on the color bar refer to the strength of the correlation in the table (red = 1, green = -1).

doi:10.1371/journal.pone.0132542.g004

immunological processes and functions, according to GO ( $q \leq .05$ ) and IPA (S6 Fig). Sixty-two percent of the probes in this module were brain-expressed (hypergeometric test,  $p = .002$ ) [42].

IQ was not significantly associated with the ASD ( $r = .038, p = .80$ ) or psychosis modules ( $r = -.26, p = .09$ ).


Gender was not significantly associated with the ASD ( $r = 0.046, p = 0.8$ ) or psychosis modules ( $r = -0.16, p = 0.3$ )

See S1 Text and S7 Fig for results of the module preservation analysis.

### Validation with published datasets

We observed significant overlap between our psychosis WGCNA module and multiple modules associated with idiopathic schizophrenia in whole blood obtained in a large Dutch sample (Fig 5A,) [58]. One module that significantly overlapped with our Purple module ( $p = 2.7e-07$ ), was also observed in an independent antipsychotic-naïve schizophrenia dataset [58]. Permutation test showed that our observed overlap lies 9 standard deviations from the median of the observed values within the empirical null distribution.

Additionally, we identified overlapping genes between the Royal Blue module and genes related to idiopathic ASD (hypergeometric test,  $p = .01$ ) [61]. Four genes in our ASD module (i.e., *CNTNAP2*, *KMO*, *MEF2C*, *PRICKLE1*) have been previously associated with idiopathic



**Fig 5. A) Visant plot of top 1500 gene connections in 22q11DS Purple module, which is significantly associated with a psychotic disorder ( $p = .03$ ) and positive symptoms ( $p = 5.0e-8$ ).** Genes that are the most strongly connected are listed in a larger font than less connected genes. Genes found in the Purple module that overlap with genes in the Salmon module, which was validated in a set of antipsychotic naïve schizophrenia patients module [51] are highlighted in red. B) Visant plot of top 1500 gene connections in 22q11DS Royal Blue module, which is significantly associated with an ASD diagnosis. Genes that are most strongly connected are listed in larger font than other, less connected genes. Genes found in the Royal Blue module that overlap with genes in M12 autism-related brain expressed module [52] are highlighted in red.

doi:10.1371/journal.pone.0132542.g005

ASD in humans [61]. There was also a trend toward overlap between this module and an autism-related ‘neuronal’ module (M12) from post-mortem brain transcriptome data obtained from idiopathic autism cases (hypergeometric test,  $p = 0.10$ , Fig 5B) [59]. *CNTNAP2*—a gene consistently implicated in the etiology of ASD and specific language impairment [62]—was again identified in both our ASD module and in the M12 module.

## Discussion

In this comprehensive investigation of genomic profiles in 22q11DS patients, we examined structural variability within the 22q11.2 locus, compared peripheral blood gene expression profiles of 22q11DS participants to unaffected controls, and utilized a systems biology approach, WGCNA, to identify genes associated with variability in phenotypic expression in 22q11DS. This is the largest study to date of genome-wide gene expression in phenotypically well-characterized patients with 22q11DS, and the first to utilize an unbiased network-based approach to investigate disrupted functional pathways in 22q11DS. We identified distinct gene expression profiles associated with psychosis and ASD in 22q11DS, which showed significant overlap with genes associated with idiopathic psychosis and ASD. These findings provide support for the notion that investigation of highly penetrant genetic variants of these disorders can guide exploration for disrupted genes and functional pathways relevant to idiopathic forms of ASD and psychosis.

### Structural variability: Deletion breakpoints

Our aCGH results confirmed that the 3 MB deletion is the most common form of the deletion [36,60,63], but also identified additional structural variability within and proximal to the deleted region. Two 22q11DS individuals with the typical 3 MB deletion also had a distal duplication that encompassed one gene, *TOP3B*, a eukaryotic DNA topoisomerase. *TOP3B* is involved in RNA metabolism through its interaction with FMRP [64], which codes for the fragile X mental retardation protein, and inhibits the translation of neuronal mRNAs [65]. Two studies have shown that single nucleotide and copy number variants of *TOP3B* are enriched in individuals with schizophrenia and ASD [66,67]. Recently, deletions of *TOP3B* were shown to be associated with both schizophrenia and intellectual disability [64]. Given the variability documented within our sample, and in the two prior studies to apply high-resolution tiling arrays to the 22q11.2 region [35,36], larger samples are needed to adequately address whether disruption of the region encompassing *TOP3B* is associated with phenotypic variability within 22q11DS.

### Differential Expression Findings

**22q11DS vs. Controls.** As anticipated, genes within the 22q11.2 locus of deleted patients were significantly down-regulated relative to controls. There was, nevertheless, substantial variability in gene expression levels within 22q11DS patients, which may be partially explained by genetic variability in functional alleles within or proximal to the 22q11.2 locus, and/or regulatory regions [27]. For example, recent findings show that, while there is an approximately 50% reduction in COMT mRNA, protein, and enzyme activity levels in 22q11DS patients overall, COMT haplotypes containing SNPs in the 3' untranslated region modulate the effect of the Val158Met genotype on COMT expression and enzyme activity [68]. Furthermore, we found that genes that were DE in 22q11DS patients vs. controls showed significant enrichment for brain-expressed genes, and top genetic networks were associated with axon guidance signaling pathways. This finding complements human neuroimaging studies reporting disrupted white matter integrity in 22q11DS, possibly driven by reduced axonal coherence [69,70]. These

brain-related alterations may be associated with characteristic phenotypes of 22q11DS (e.g., social cognition and visual-spatial processing deficits) [71].

**Psychosis.** Our GO analyses revealed an over-representation of genes associated with mitochondrial organization and transport in genes DE in 22q11DS patients with a psychotic disorder. Recent studies have implicated mitochondrial dysfunction in the pathophysiology of (idiopathic) schizophrenia [72], as transcriptome alterations in genes associated with mitochondrial functioning has been found in postmortem brain tissue of individuals with schizophrenia [73,74]. However, it is unknown whether mitochondrial dysfunction in schizophrenia is due to a genetic liability, a secondary response to neurotransmitter dysfunction, or a consequence of environmental toxins [75]. Furthermore, there is evidence that mitochondrial dysfunction is also involved in other psychiatric disorders [76]. These findings, paired with the fact that a subset of the genes within the 22q11 region encode mitochondrial proteins [77], suggest that the relationship between mitochondrial dysfunction and psychiatric disorders in those with 22q11DS should be investigated further.

## Weighted Gene Coexpression Network Findings

It is noteworthy that we did not find a significant enrichment of brain expressed genes when we looked at genes differentially expressed in 22q11DS patients with ASD and psychosis, respectively, but the WGCNA modules associated with the clinical phenotypes were significantly enriched for brain expressed genes. This discrepancy is likely due to the different analytic methods used. WGCNA examines the level of co-expression between genes and identifies transcripts that are not up- or down- regulated in the respective psychiatric conditions. Thus, it appears that WGCNA able to identify more brain-related genes associated with the clinical phenotype than the DE analysis.

**Psychosis.** Our results indicate distinct genome-wide transcriptional changes relevant to phenotypic expression of psychosis in 22q11DS patients. We identified a module of functionally connected genes that was associated with categorical and dimensional measures of psychosis. This module showed significant overlap with modules previously associated with idiopathic schizophrenia and was not related to antipsychotic medication use. The top network associated with this module was RNA post-transcriptional modification. Alterations of micro-RNA expression, which is involved in post-transcription regulation of gene expression, have been identified in post-mortem prefrontal cortical brain tissue of schizophrenia patients. [78,79] Additionally, disruptions in RNA metabolism are a molecular signature common to many neurodevelopmental disorders [80].

Given the emerging body of evidence linking immune system pathways to schizophrenia and psychosis vulnerability [81], it should be noted that we originally identified significant enrichment of genes associated with immune response in the WGCNA psychosis module; however, these terms did not survive correction for multiple comparisons ( $q$ -value range: .07-.08). Indeed our psychosis module included several immune-related genes, including *TLR7*, which is part of a class of genes called toll-like receptors, whose molecules activate an inflammation response and have been shown to be elevated in peripheral blood of those with psychotic disorders [82]. Recently, suggestive evidence for neuroinflammation in idiopathic schizophrenia has been provided by novel free water diffusion imaging methods indicating increased extracellular volume in patients in a first episode of schizophrenia [83]. Thus, the role of inflammatory processes in the etiology of psychosis, both in 22q11DS and in the broader population, will be important to further investigate in future studies.

**Autism Spectrum Disorder.** Both DE analysis and WGCNA showed converging evidence that alterations in immune-related pathways are associated with ASD. We identified a module

of co-expressed genes, significantly associated with ASD, which also contained multiple genes that have previously been associated with idiopathic ASD (*CNTNAP2*, *KMO*, *MEF2C*, *PRICKLE1* [84–87]). Post-mortem studies have identified increased micro- and astro-glial reactions in multiple brain regions in idiopathic ASD [88–90], coupled with up-regulation of pro- and anti-inflammatory cytokines [88]. Together, these findings suggest that ASD pathology may be related to an innate immune system response to neuronal disturbances.

There is debate over whether the ASD and psychosis phenotypes within 22q11DS are considered to be distinct phenomena. [27,30,91]. Our findings of independent gene expression modules associated with psychosis and ASD in 22q11DS support the notion that these two disorders are distinct phenomena. However, an inherent limitation to our cross-sectional study is that we do not know which 22q11DS participants will subsequently develop a psychotic disorder, given the age range of our sample. Inclusion of such ‘false negative’ cases in our non-psychotic group would presumably add noise to our data, reducing our ability to obtain significant results rather than leading to spurious statistically significant findings. Nevertheless, prospective, longitudinal studies are necessary to fully address this question.

It should be noted that there is debate over the prevalence of ASD diagnosis in 22q11DS. Though a high prevalence of ASD in 22q11DS has been reported in multiple publications (~14–50%, [14–17]), others have suggested that the incidence of ASD (strictly defined) is not elevated [92]. Some researchers have proposed that early social dysfunction in 22q11DS is associated with premorbidity to schizophrenia, and that these social impairments may result in a misdiagnosis of an ASD [27,91]. However, other studies indicate that a probable childhood diagnosis of ASD does *not* predict later psychotic disorder [30]. Certain methodological approaches, such as reliance only upon collateral report, may inflate the actual number of individuals diagnosed with ASD [92]. Direct comparison of children with idiopathic ASD versus youth with 22q11DS and an ASD diagnosis (using the ADI-R), found that certain features characteristic of idiopathic autism, such as idiosyncratic speech and social reciprocity deficits, were spared in 22q11DS-ASD+ [93]. However, there were also many similarities between the two groups, as they both exhibited impaired non-verbal social communication, inability to use make-believe during play, motor stereotypies and repetitive use of objects, rituals, and difficulties with peer relationships [93]. It is most likely that children with 22q11DS share some phenotypic features with idiopathic ASD, but have a unique behavioral phenotype that does not fit neatly into defined diagnostic boundaries [25]. Future prospective studies that use information from multiple sources (participants and collateral) and examine the relationships between identified ASD symptoms and other psychopathology over time are necessary to determine the validity and stability of ASD diagnoses in 22q11DS.

## Limitations

Several limitations to the current study should be noted. Although brain tissue from early stages of disease might be optimal, it is not available in patients with 22q11DS, and most pathological specimens are from deceased individuals with long disease duration. Whole-blood gene expression profiles have been found to share significant similarities, but not perfect correspondence, with those of multiple CNS tissues [94–97]. Given that there are no publicly available 22q11DS post-mortem databanks, using peripheral blood to examine gene expression is an important first step. Although peripheral blood cannot replace CNS tissue, it may provide a suitable surrogate, particularly when post-mortem brain tissue is not available. Finally, more consistent and reproducible effects on gene expression are likely to be obtained in patients with homogeneous genetic etiology(4) like 22q11DS.



The number of subjects in our dataset with psychosis in particular was small and several of the analyses were not corrected for multiple comparisons; additional datasets of peripheral blood and other tissues from 22q11DS patients are needed to confirm these findings. To maximize the sample size for our primary analyses, we chose to include all available 22q11DS patients and healthy controls. Thus, not all of our samples were independent of each other. However, results of a secondary analysis (22q11DS cases vs. a subset of age-matched, unrelated controls;  $N = 39$ ) was highly comparable to the overall analysis, indicating that our primary results were not attributable to non-independence in the control group. However, age effects on gene expression, both within and outside of the 22q11.2 locus, warrant further systematic investigation. Future analyses may also benefit from using more sensitive technology (i.e., RNA sequencing) to identify splicing events, non-coding RNAs, and novel transcripts [98,99].

## Conclusion

Collectively, these findings provide a first step toward understanding the functional gene networks disrupted by the 22q11.2 deletion, which may relate to variable phenotypic expression of the disorder. Future investigations in human *in vitro* cellular models and in animal models of 22q11.2 mutations are necessary to link the affected genetic pathways to molecular mechanisms, which may be targeted for biologically informed interventions.

## Supporting Information

**S1 Text. Methods for CGH and WGCNA analyses, results of secondary analyses conducted.**  
(DOC)

**S1 R Code. R code for WGCNA analysis.**  
(DOCX)

**S1 Fig. Box plots of genes of genes in the 22q11.2 locus with significant differential expression levels in 22q11DS patients relative to controls.**  
(DOCX)

**S2 Fig. Top network associated with differentially expressed genes in 22q11DS-PSY+ ( $p < .005$ ).**  
(DOCX)

**S3 Fig. Top network associated with differentially expressed genes in 22q11DS-ASD+ ( $p < .005$ ).**  
(DOCX)

**S4 Fig. Relationship between COMT gene expression level and age in controls ( $r = .27$ ,  $p = .027$ ).**  
(DOCX)

**S5 Fig. Gene ontology (GO) analysis and Ingenuity Pathway Analysis for the Purple module.**  
(DOCX)

**S6 Fig. Gene ontology analysis and Ingenuity Pathway Analysis for the Royal Blue module.**  
(DOCX)

**S7 Fig. Module preservation analysis.**  
(DOCX)

**S8 Fig. Top network associated with differentially expressed genes in 22q11DS-PSY- vs. controls ( $p < .005$ ).**

(DOCX)

**S9 Fig. Top network associated with differentially expressed genes in 22q11DS-PSY+ vs. controls ( $p < .005$ ).**

(DOCX)

**S1 Table. Psychotropic medication information for 22q11DS patients.**

(DOCX)

**S2 Table. Differentially expressed probes (significant at 5% FDR) in 22q11DS (N = 46) vs. controls (N = 66).**

(DOCX)

**S3 Table. Differentially expressed probes (significant at 5% FDR) in 22q11DS-PSY+ (N = 6) vs. 22q11DS-PSY- (N = 40).**

(DOCX)

**S4 Table. Differentially expressed probes significant (at 5% FDR) in 22q11DS-ASD+ (N = 15) vs. 22q11DS-ASD- (N = 25).**

(DOCX)

**S5 Table. List of genes in the Purple module, which was significantly associated with psychotic disorder diagnosis in 22q11DS.**

(DOCX)

**S6 Table. List of genes in the Royal Blue module, which was significantly associated with an ASD diagnosis in 22q11DS.**

(DOCX)

## Acknowledgments

We thank the participants and their families for being a part of our research.

## Author Contributions

Conceived and designed the experiments: GC DHG CEB MJ FG MTL. Performed the experiments: GC FG. Analyzed the data: FG MJ MTL AH. Contributed reagents/materials/analysis tools: CEB GC DHG. Wrote the paper: MJ CEB GC DHG AH MTL. Recruited patients and collected data: CC.

## References

1. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. *Nature*. 2010 Jul; 466(7304):368–72. doi: [10.1038/nature09146](https://doi.org/10.1038/nature09146) PMID: [20531469](https://pubmed.ncbi.nlm.nih.gov/20531469/)
2. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, et al. Strong association of de novo copy number mutations with autism. *Science*. 2007 Apr 20; 316(5823):445–9. PMID: [17363630](https://pubmed.ncbi.nlm.nih.gov/17363630/)
3. Stefansson H, Rujescu D, Cichon S, Pietiläinen OPH, Ingason A, Steinberg S, et al. Large recurrent microdeletions associated with schizophrenia. *Nature*. 2008 Sep 11; 455(7210):232–6. doi: [10.1038/nature07229](https://doi.org/10.1038/nature07229) PMID: [18668039](https://pubmed.ncbi.nlm.nih.gov/18668039/)
4. Nishimura Y, Martin CL, Vazquez-Lopez A, Spence SJ, Alvarez-Retuerto AI, Sigman M, et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. *Hum Mol Genet*. 2007 Apr 27; 16(14):1682–98. PMID: [17519220](https://pubmed.ncbi.nlm.nih.gov/17519220/)

5. Paşca SP, Portmann T, Voineagu I, Yazawa M, Shcheglovitov A, Paşca AM, et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. *Nat Med*. 2011 Nov 27; 17(12):1657–62. doi: [10.1038/nm.2576](https://doi.org/10.1038/nm.2576) PMID: [22120178](https://pubmed.ncbi.nlm.nih.gov/22120178/)
6. Jonas RK, Montojo CA, Bearden CE. The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. *Biological Psychiatry*. Elsevier; 2013 Aug 27;:1–10.
7. Green T, Gothelf D, Glaser B, Debbané M, Frisch A, Kotler M, et al. Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. *J Am Acad Child Adolesc Psychiatry*. 2009 Nov; 48(11):1060–8. doi: [10.1097/CHI.0b013e3181b76683](https://doi.org/10.1097/CHI.0b013e3181b76683) PMID: [19797984](https://pubmed.ncbi.nlm.nih.gov/19797984/)
8. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. *J Nerv Ment Dis*. 1994 Aug; 182(8):476–8. PMID: [8040660](https://pubmed.ncbi.nlm.nih.gov/8040660/)
9. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. *Arch Gen Psychiatry*. 1999 Oct; 56(10):940–5. PMID: [10530637](https://pubmed.ncbi.nlm.nih.gov/10530637/)
10. Gothelf D, Presburger G, Zohar AH, Burg M, Nahmani A, Frydman M, et al. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. *Am J Med Genet B Neuropsychiatr Genet*. 2004 Apr; 126B(1):99–105. PMID: [15048657](https://pubmed.ncbi.nlm.nih.gov/15048657/)
11. Gothelf D, Feinstein C, Thompson T, Gu E, Penniman L, Van Stone E, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. *Am J Psychiatry*. 2007 Apr; 164(4):663–9. PMID: [17403981](https://pubmed.ncbi.nlm.nih.gov/17403981/)
12. Fung WLA, McEvilly R, Fong J, Silversides C, Chow E, Bassett A. Elevated prevalence of generalized anxiety disorder in adults with 22q11.2 deletion syndrome. *Am J Psychiatry*. 2010 Aug; 167(8):998. doi: [10.1176/appi.ajp.2010.09101463](https://doi.org/10.1176/appi.ajp.2010.09101463) PMID: [20693476](https://pubmed.ncbi.nlm.nih.gov/20693476/)
13. Schneider M, Debbané M, Bassett AS, Chow EWC, Fung WLA, van den Bree MBM, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. *Am J Psychiatry*. 2014 Feb.
14. Vorstman JAS, Morcus MEJ, Duijff SN, Klaassen PWJ, Heineman-de Boer JA, Beemer FA, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. *J Am Acad Child Adolesc Psychiatry*. 2006 Sep; 45(9):1104–13. PMID: [16926618](https://pubmed.ncbi.nlm.nih.gov/16926618/)
15. Antshel KM, Aneja A, Strunge L, Peebles J, Fremont WP, Stallone K, et al. Autistic spectrum disorders in velo-cardio facial syndrome (22q11.2 deletion). *J Autism Dev Disord*. 2007 Oct; 37(9):1776–86. PMID: [17180713](https://pubmed.ncbi.nlm.nih.gov/17180713/)
16. Niklasson L, Rasmussen P, Oskarsdóttir S, Gillberg C. Neuropsychiatric disorders in the 22q11 deletion syndrome. *Genet Med*. 2001 Jan; 3(1):79–84. PMID: [11339385](https://pubmed.ncbi.nlm.nih.gov/11339385/)
17. Niklasson L, Rasmussen P, Oskarsdóttir S, Gillberg C. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome. *Research in Developmental Disabilities*. 2009 Jul; 30(4):763–73. doi: [10.1016/j.ridd.2008.10.007](https://doi.org/10.1016/j.ridd.2008.10.007) PMID: [19070990](https://pubmed.ncbi.nlm.nih.gov/19070990/)
18. Bertolino A, Caforio G, Petruzzella V, Latorre V, Rubino V, Dimalta S, et al. Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance. *Psychiatry Research*. 2006 Oct; 147(2–3):221–6. PMID: [16952445](https://pubmed.ncbi.nlm.nih.gov/16952445/)
19. Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, Fazio L, et al. Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. *Biol Psychiatry*. 2006 Dec; 60(11):1250–8. PMID: [16950222](https://pubmed.ncbi.nlm.nih.gov/16950222/)
20. Gadow KD, Roohi J, DeVincent CJ, Kirsch S, Hatchwell E. Association of COMT (Val158Met) and BDNF (Val66Met) gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. *J Autism Dev Disord*. 2009 Nov; 39(11):1542–51. doi: [10.1007/s10803-009-0794-4](https://doi.org/10.1007/s10803-009-0794-4) PMID: [19582565](https://pubmed.ncbi.nlm.nih.gov/19582565/)
21. Williams NM, Glaser B, Norton N, Williams H, Pierce T, Moskva V, et al. Strong evidence that GNB1L is associated with schizophrenia. *Hum Mol Genet*. 2007 Nov 7; 17(4):555–66. PMID: [18003636](https://pubmed.ncbi.nlm.nih.gov/18003636/)
22. Prata DP, Mechelli A, Fu CHY, Picchioni M, Kane F, Kalidindi S, et al. Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. *Biol Psychiatry*. 2009 Mar; 65(6):473–80. doi: [10.1016/j.biopsych.2008.09.027](https://doi.org/10.1016/j.biopsych.2008.09.027) PMID: [19054502](https://pubmed.ncbi.nlm.nih.gov/19054502/)
23. Yoo HJ, Cho IH, Park M, Yang SY, Kim SA. Association of the catechol-o-methyltransferase gene polymorphisms with Korean autism spectrum disorders. *J Korean Med Sci*. 2013 Sep; 28(9):1403–6. doi: [10.3346/jkms.2013.28.9.1403](https://doi.org/10.3346/jkms.2013.28.9.1403) PMID: [24015051](https://pubmed.ncbi.nlm.nih.gov/24015051/)
24. Li Y, Zhao Q, Wang T, Liu J, Li J, Li T, et al. Association study between GNB1L and three major mental disorders in Chinese Han populations. *Psychiatry Research*. 2011 May; 187(3):457–9. doi: [10.1016/j.psychres.2010.04.019](https://doi.org/10.1016/j.psychres.2010.04.019) PMID: [20538345](https://pubmed.ncbi.nlm.nih.gov/20538345/)

25. Baker K, Vorstman JAS. Is there a core neuropsychiatric phenotype in 22q11.2 deletion syndrome? *Current Opinion in Neurology*. 2012 Apr; 25(2):131–7. doi: [10.1097/WCO.0b013e328352dd58](https://doi.org/10.1097/WCO.0b013e328352dd58) PMID: [22395003](https://pubmed.ncbi.nlm.nih.gov/22395003/)
26. Jolin EM, Weller RA, Jessani NR, Zackai EH, McDonald-McGinn DM, Weller EB. Affective disorders and other psychiatric diagnoses in children and adolescents with 22q11.2 Deletion Syndrome. *Journal of Affective Disorders*. 2009 Dec; 119(1–3):177–80. doi: [10.1016/j.jad.2009.02.016](https://doi.org/10.1016/j.jad.2009.02.016) PMID: [19269692](https://pubmed.ncbi.nlm.nih.gov/19269692/)
27. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. *Nat Rev Neurosci*. 2010 Jun; 11(6):402–16. doi: [10.1038/nm2841](https://doi.org/10.1038/nm2841) PMID: [20485365](https://pubmed.ncbi.nlm.nih.gov/20485365/)
28. Couture SM, Penn DL, Losh M, Adolphs R, Hurley R, Piven J. Comparison of social cognitive functioning in schizophrenia and high functioning autism: more convergence than divergence. *Psychol Med*. 2010 Apr; 40(4):569–79. doi: [10.1017/S003329170999078X](https://doi.org/10.1017/S003329170999078X) PMID: [19671209](https://pubmed.ncbi.nlm.nih.gov/19671209/)
29. Pinkham AE, Hopfinger JB, Pelphrey KA, Piven J, Penn DL. Neural Bases for Impaired Social Cognition in Schizophrenia and Autism Spectrum Disorders. *Schizophrenia Research*. 2008 Feb; 99(1–3):164–75. PMID: [18053686](https://pubmed.ncbi.nlm.nih.gov/18053686/)
30. Vorstman JAS, Breetvelt EJ, Thode KI, Chow EWC, Bassett AS. Expression of autism spectrum and schizophrenia in patients with a 22q11.2 deletion. *Schizophrenia Research*. Elsevier B.V.; 2013 Jan 1; 143(1):55–9. doi: [10.1016/j.schres.2012.10.010](https://doi.org/10.1016/j.schres.2012.10.010) PMID: [23153825](https://pubmed.ncbi.nlm.nih.gov/23153825/)
31. Kasprzyk A. BioMart: driving a paradigm change in biological data management. *Database (Oxford)*. 2011; 2011:bar049.
32. Hiramoto T, Kang G, Suzuki G, Satoh Y, Kucherlapati R, Watanabe Y, et al. Tbx1: identification of a 22q11.2 gene as a risk factor for autism spectrum disorder in a mouse model. *Hum Mol Genet*. 2011 Dec; 20(24):4775–85. doi: [10.1093/hmg/ddr404](https://doi.org/10.1093/hmg/ddr404) PMID: [21908517](https://pubmed.ncbi.nlm.nih.gov/21908517/)
33. Toritsuka M, Kimoto S, Muraki K, Landek-Salgado MA, Yoshida A, Yamamoto N, et al. Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental deficits in a 22q11 deletion syndrome mouse model. *Proc Natl Acad Sci U S A*. 2013 Oct; 110(43):17552–7. doi: [10.1073/pnas.1312661110](https://doi.org/10.1073/pnas.1312661110) PMID: [24101523](https://pubmed.ncbi.nlm.nih.gov/24101523/)
34. Shaikh TH, Kurahashi H, Saitta SC, O'Hare AM, Hu P, Roe BA, et al. Chromosome 22-specific low copy repeats and the 22q11.2 deletion syndrome: genomic organization and deletion endpoint analysis. *Hum Mol Genet*. 2000 Mar; 9(4):489–501. PMID: [10699172](https://pubmed.ncbi.nlm.nih.gov/10699172/)
35. Shaikh TH, O'Connor RJ, Pierpont ME, McGrath J, Hacker AM, Nimmakayalu M, et al. Low copy repeats mediate distal chromosome 22q11.2 deletions: sequence analysis predicts breakpoint mechanisms. *Genome Res*. 2007 Apr; 17(4):482–91. PMID: [17351135](https://pubmed.ncbi.nlm.nih.gov/17351135/)
36. Urban AE, Korbel JO, Selzer R, Richmond T, Hacker A, Popescu GV, et al. High-resolution mapping of DNA copy alterations in human chromosome 22 using high-density tiling oligonucleotide arrays. *Proc Natl Acad Sci U S A*. 2006 Mar; 103(12):4534–9. PMID: [16537408](https://pubmed.ncbi.nlm.nih.gov/16537408/)
37. Bittel DC, Yu S, Newkirk H, Kibiryaeva N, Holt A3, Butler MG, et al. Refining the 22q11.2 deletion breakpoints in DiGeorge syndrome by aCGH. *Cytogenet Genome Res*. 2009; 124(2):113–20. doi: [10.1159/000207515](https://doi.org/10.1159/000207515) PMID: [19420922](https://pubmed.ncbi.nlm.nih.gov/19420922/)
38. van Beveren NJM, Krab LC, Swagemakers S, Buitendijk GHS, Boot E, van der Spek P, et al. Functional gene-expression analysis shows involvement of schizophrenia-relevant pathways in patients with 22q11 deletion syndrome. *PLoS ONE*. 2012; 7(3):e33473. doi: [10.1371/journal.pone.0033473](https://doi.org/10.1371/journal.pone.0033473) PMID: [22457764](https://pubmed.ncbi.nlm.nih.gov/22457764/)
39. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Stat Appl Genet Mol Biol*. 2005; 4:Article17.
40. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics*. 2008; 9:559. doi: [10.1186/1471-2105-9-559](https://doi.org/10.1186/1471-2105-9-559) PMID: [19114008](https://pubmed.ncbi.nlm.nih.gov/19114008/)
41. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. *J Am Acad Child Adolesc Psychiatry*. 2000 Jan; 39(1):28–38. PMID: [10638065](https://pubmed.ncbi.nlm.nih.gov/10638065/)
42. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. Spatio-temporal transcriptome of the human brain. *Nature*. 2011 Oct; 478(7370):483–9. doi: [10.1038/nature10523](https://doi.org/10.1038/nature10523) PMID: [22031440](https://pubmed.ncbi.nlm.nih.gov/22031440/)
43. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research, New York State Psychiatric Institute; 2002 Nov.
44. McGlashan T, Miller TJ, Woods SW, Hoffman RE, Davidson L. A scale for the assessment of prodromal symptoms and states. In: Miller TJ, Mednick SA, McGlashan T, Libeiger J, Johannessen JO, editors. *Early Intervention in Psychotic Disorders*. Kluwer Academic Publishers; 2001. pp. 135–49.

45. Lord C, Risi S, Lambrecht L, Cook EHJ, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord*. 2000 Jun; 30(3):205–23. PMID: [11055457](#)
46. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord*. 1994 Oct; 24(5):659–85. PMID: [7814313](#)
47. Ho JS, Radoeva PD, Jalbrzikowski M, Chow C, Hopkins J, Tran W-C, et al. Deficits in Mental State Attributions in Individuals with 22q11.2 Deletion Syndrome (Velo-Cardio-Facial Syndrome). *Autism Res*. 2012 Sep 7; 5(6):407–18. doi: [10.1002/aur.1252](#) PMID: [22962003](#)
48. Coppola G. Designing, performing, and interpreting a microarray-based gene expression study. *Methods Mol Biol*. 2011; 793:417–39. doi: [10.1007/978-1-61779-328-8\\_28](#) PMID: [21913117](#)
49. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. *BMC Mol Biol*. 2006; 7:3. PMID: [16448564](#)
50. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol*. 2004; 3:Article3.
51. Coppola G, Burnett R, Perlman S, Versano R, Gao F, Plasterer H, et al. A gene expression phenotype in lymphocytes from Friedreich ataxia patients. *Ann Neurol*. 2011 Nov; 70(5):790–804. doi: [10.1002/ana.22526](#) PMID: [22162061](#)
52. Johnson MB, Kawasawa YI, Mason CE, Krsnik Z, Coppola G, Bogdanovic D, et al. Functional and evolutionary insights into human brain development through global transcriptome analysis. *Neuron*. 2009 May; 62(4):494–509. doi: [10.1016/j.neuron.2009.03.027](#) PMID: [19477152](#)
53. Rivals I, Personnaz L, Taing L, Potier M-C. Enrichment or depletion of a GO category within a class of genes: which test? *Bioinformatics*. 2007 Feb; 23(4):401–7. PMID: [17182697](#)
54. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*. JSTOR; 1995;:289–300.
55. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. *Nature*. 2005 Oct; 437(7061):1032–7. PMID: [16136080](#)
56. Geschwind DH, Konopka G. Neuroscience in the era of functional genomics and systems biology. *Nature*. 2009 Oct; 461(7266):908–15. doi: [10.1038/nature08537](#) PMID: [19829370](#)
57. Langfelder P, Luo R, Oldham MC, Horvath S. Is my network module preserved and reproducible? *PLoS Comput Biol*. 2011; 7(1):e1001057. doi: [10.1371/journal.pcbi.1001057](#) PMID: [21283776](#)
58. de Jong S, Boks MPM, Fuller TF, Strengman E, Janson E, de Kovel CGF, et al. A Gene Co-Expression Network in Whole Blood of Schizophrenia Patients Is Independent of Antipsychotic-Use and Enriched for Brain-Expressed Genes. Mazza M, editor. *PLoS ONE*. 2012 Jun 27; 7(6):e39498. doi: [10.1371/journal.pone.0039498](#) PMID: [22761806](#)
59. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature*. 2011 Jun; 474(7351):380–4. doi: [10.1038/nature10110](#) PMID: [21614001](#)
60. Edlmann L, Pandita RK, Morrow BE. Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome. *Am J Hum Genet*. 1999 Apr; 64(4):1076–86. PMID: [10090893](#)
61. Basu SN, Kollu R, Banerjee-Basu S. AutDB: a gene reference resource for autism research. *Nucleic Acids Res*. 2009 Jan; 37(Database issue):D832–6. doi: [10.1093/nar/gkn835](#) PMID: [19015121](#)
62. Penagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell*. 2011 Sep; 147(1):235–46. doi: [10.1016/j.cell.2011.08.040](#) PMID: [21962519](#)
63. Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, et al. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. *Am J Hum Genet*. 1997 Sep; 61(3):620–9. PMID: [9326327](#)
64. Stoll G, Pietiläinen OPH, Linder B, Suvisaari J, Brosi C, Hennah W, et al. Deletion of TOP3β, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. *Nature Publishing Group*. 2013 Aug 4; 16(9):1228–37.
65. Lagerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. Evidence that fragile X mental retardation protein is a negative regulator of translation. *Hum Mol Genet*. 2001 Feb; 10(4):329–38. PMID: [11157796](#)
66. Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. *Nat Genet*. 2012 Oct 3; 44(12):1365–9. doi: [10.1038/ng.2446](#) PMID: [23042115](#)

67. Darnell JC, Van Driesche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell*. 2011 Jul; 146(2):247–61. doi: [10.1016/j.cell.2011.06.013](https://doi.org/10.1016/j.cell.2011.06.013) PMID: [21784246](https://pubmed.ncbi.nlm.nih.gov/21784246/)
68. Gothelf D, Law AJ, Frisch A, Chen J, Zarchi O, Michaelovsky E, et al. Biological Effects of COMT Haplotypes and Psychosis Risk in 22q11.2 Deletion Syndrome. *Biol Psychiatry*. Elsevier; 2014 Mar 1; 75(5):406–13. doi: [10.1016/j.biopsych.2013.07.021](https://doi.org/10.1016/j.biopsych.2013.07.021) PMID: [23992923](https://pubmed.ncbi.nlm.nih.gov/23992923/)
69. Radoeva PD, Coman IL, Antshel KM, Fremont W, McCarthy CS, Kotkar A, et al. Atlas-based white matter analysis in individuals with velo-cardio-facial syndrome (22q11.2 deletion syndrome) and unaffected siblings. *Behav Brain Funct*. 2012; 8:38. doi: [10.1186/1744-9081-8-38](https://doi.org/10.1186/1744-9081-8-38) PMID: [22853778](https://pubmed.ncbi.nlm.nih.gov/22853778/)
70. Kikinis Z, Asami T, Bouix S, Finn CT, Ballinger T, Tworog-Dube E, et al. Reduced fractional anisotropy and axial diffusivity in white matter in 22q11.2 deletion syndrome: a pilot study. *Schizophrenia Research*. Elsevier B.V; 2012 Oct 1; 141(1):35–9. doi: [10.1016/j.schres.2012.06.032](https://doi.org/10.1016/j.schres.2012.06.032) PMID: [22863550](https://pubmed.ncbi.nlm.nih.gov/22863550/)
71. Sigurdsson T, Stark KL, Karayiorgou M, Gogos JA, Gordon JA. Impaired hippocampal. *Nature*. Nature Publishing Group; 2010 Jan 4; 464(7289):763–7. doi: [10.1038/nature08855](https://doi.org/10.1038/nature08855) PMID: [20360742](https://pubmed.ncbi.nlm.nih.gov/20360742/)
72. Goncalves VF, Andreatza AC, Kennedy JL. Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. *Hum Genet*. 2015 Jan; 134(1):13–21. doi: [10.1007/s00439-014-1491-8](https://doi.org/10.1007/s00439-014-1491-8) PMID: [25312050](https://pubmed.ncbi.nlm.nih.gov/25312050/)
73. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT-J, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Molecular Psychiatry*. 2004 Jul; 9(7):684–97–643. PMID: [15098003](https://pubmed.ncbi.nlm.nih.gov/15098003/)
74. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. *Hum Mol Genet*. 2005 Jan; 14(2):241–53. PMID: [15563509](https://pubmed.ncbi.nlm.nih.gov/15563509/)
75. Clay HB, Sullivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. *Int J Dev Neurosci*. 2011 May; 29(3):311–24. doi: [10.1016/j.ijdevneu.2010.08.007](https://doi.org/10.1016/j.ijdevneu.2010.08.007) PMID: [20833242](https://pubmed.ncbi.nlm.nih.gov/20833242/)
76. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, et al. Impaired mitochondrial function in psychiatric disorders. *Nat Rev Neurosci*. 2012 May; 13(5):293–307. doi: [10.1038/nrn3229](https://doi.org/10.1038/nrn3229) PMID: [22510887](https://pubmed.ncbi.nlm.nih.gov/22510887/)
77. Maynard TM, Meechan DW, Dudevoir ML, Gopalakrishna D, Peters AZ, Heindel CC, et al. Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes. *Mol Cell Neurosci*. 2008 Nov; 39(3):439–51. doi: [10.1016/j.mcn.2008.07.027](https://doi.org/10.1016/j.mcn.2008.07.027) PMID: [18775783](https://pubmed.ncbi.nlm.nih.gov/18775783/)
78. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. *Genome Biol*. 2007; 8(2):R27. PMID: [17326821](https://pubmed.ncbi.nlm.nih.gov/17326821/)
79. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. *Schizophrenia Research*. 2010 Dec; 124(1–3):183–91. doi: [10.1016/j.schres.2010.07.002](https://doi.org/10.1016/j.schres.2010.07.002) PMID: [20675101](https://pubmed.ncbi.nlm.nih.gov/20675101/)
80. Nott A, Tsai L-H. The Top3beta way to untangle RNA. *Nat Neurosci*. 2013 Sep; 16(9):1163–4. doi: [10.1038/nn.3506](https://doi.org/10.1038/nn.3506) PMID: [23982446](https://pubmed.ncbi.nlm.nih.gov/23982446/)
81. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. *Biol Psychiatry*. 2014 Feb; 75(4):324–31. doi: [10.1016/j.biopsych.2013.09.037](https://doi.org/10.1016/j.biopsych.2013.09.037) PMID: [24286760](https://pubmed.ncbi.nlm.nih.gov/24286760/)
82. McKernan DP, Dennison U, Gaszner G, Cryan JF, Dinan TG. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. *Transl Psychiatry*. 2011; 1:e36. doi: [10.1038/tp.2011.37](https://doi.org/10.1038/tp.2011.37) PMID: [22832610](https://pubmed.ncbi.nlm.nih.gov/22832610/)
83. Pasternak O, Westin C-F, Bouix S, Seidman LJ, Goldstein JM, Woo T-UW, et al. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. *J Neurosci*. 2012 Nov; 32(48):17365–72. doi: [10.1523/JNEUROSCI.2904-12.2012](https://doi.org/10.1523/JNEUROSCI.2904-12.2012) PMID: [23197727](https://pubmed.ncbi.nlm.nih.gov/23197727/)
84. McFarlane HG, Kusek GK, Yang M, Phoenix JL, Bolivar VJ, Crawley JN. Autism-like behavioral phenotypes in BTBR T+tf/J mice. *Genes Brain Behav*. 2008 Mar; 7(2):152–63. PMID: [17559418](https://pubmed.ncbi.nlm.nih.gov/17559418/)
85. Paemka L, Mahajan VB, Skeie JM, Sowers LP, Ehaideb SN, Gonzalez-Alegre P, et al. PRICKLE1 interaction with SYNAPSIN I reveals a role in autism spectrum disorders. *PLoS ONE*. 2013; 8(12):e80737. doi: [10.1371/journal.pone.0080737](https://doi.org/10.1371/journal.pone.0080737) PMID: [24312498](https://pubmed.ncbi.nlm.nih.gov/24312498/)
86. Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge KD, Rutledge SL, et al. Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. *Am J Med Genet*. 2011 Aug 16; 155(10):2386–96.

87. Arking DE, Cutler DJ, Brune CW, Teslovich TM, West K, Ikeda M, et al. A Common Genetic Variant in the Neurexin Superfamily Member CNTNAP2 Increases Familial Risk of Autism. *The American Journal of Human Genetics*. 2008 Jan; 82(1):160–4.
88. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann Neurol*. 2004; 57(1):67–81.
89. Morgan JT, Chana G, Abramson I, Semendeferi K, Courchesne E, Everall IP. Abnormal microglial–neuronal spatial organization in the dorsolateral prefrontal cortex in autism. *Brain Research*. 2012 May; 1456:72–81. doi: [10.1016/j.brainres.2012.03.036](https://doi.org/10.1016/j.brainres.2012.03.036) PMID: [22516109](https://pubmed.ncbi.nlm.nih.gov/22516109/)
90. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li X-M, et al. Elevated immune response in the brain of autistic patients. *J Neuroimmunol*. 2009 Feb; 207(1–2):111–6. doi: [10.1016/j.jneuroim.2008.12.002](https://doi.org/10.1016/j.jneuroim.2008.12.002) PMID: [19157572](https://pubmed.ncbi.nlm.nih.gov/19157572/)
91. Eliez S. Autism in children with 22q11.2 deletion syndrome. *J Am Acad Child Adolesc Psychiatry*. 2007 Apr; 46(4):433–4–authorreply434–4.
92. Angkustsiri K, Goodlin-Jones B, Deprey L, Brahmbhatt K, Harris S, Simon TJ. Social impairments in chromosome 22q11.2 deletion syndrome (22q11.2DS): autism spectrum disorder or a different endophenotype? *J Autism Dev Disord*. 2014 Apr; 44(4):739–46. doi: [10.1007/s10803-013-1920-x](https://doi.org/10.1007/s10803-013-1920-x) PMID: [24045981](https://pubmed.ncbi.nlm.nih.gov/24045981/)
93. Kates WR, Antshel KM, Fremont WP, Shprintzen RJ, Strunge LA, Burnette CP, et al. Comparing phenotypes in patients with idiopathic autism to patients with velocardiofacial syndrome (22q11 DS) with and without autism. *Am J Med Genet A*. 2007 Nov; 143A(22):2642–50. PMID: [17937445](https://pubmed.ncbi.nlm.nih.gov/17937445/)
94. Jasinska AJ, Service S, Choi O-W, DeYoung J, Grujic O, Kong S-Y, et al. Identification of brain transcriptional variation reproduced in peripheral blood: an approach for mapping brain expression traits. *Hum Mol Genet*. 2009 Nov; 18(22):4415–27. doi: [10.1093/hmg/ddp397](https://doi.org/10.1093/hmg/ddp397) PMID: [19692348](https://pubmed.ncbi.nlm.nih.gov/19692348/)
95. Cai C, Langfelder P, Fuller TF, Oldham MC, Luo R, van den Berg LH, et al. Is human blood a good surrogate for brain tissue in transcriptional studies? *BMC Genomics*. 2010; 11:589. doi: [10.1186/1471-2164-11-589](https://doi.org/10.1186/1471-2164-11-589) PMID: [20961428](https://pubmed.ncbi.nlm.nih.gov/20961428/)
96. Rollins B, Martin MV, Morgan L, Vawter MP. Analysis of whole genome biomarker expression in blood and brain. *Am J Med Genet B Neuropsychiatr Genet*. 2010 Jun; 153B(4):919–36. doi: [10.1002/ajmg.b.31062](https://doi.org/10.1002/ajmg.b.31062) PMID: [20127885](https://pubmed.ncbi.nlm.nih.gov/20127885/)
97. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. *Am J Med Genet B Neuropsychiatr Genet*. 2006 Apr; 141B(3):261–8. PMID: [16526044](https://pubmed.ncbi.nlm.nih.gov/16526044/)
98. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. *Genome Res*. 2008 Sep; 18(9):1509–17. doi: [10.1101/gr.079558.108](https://doi.org/10.1101/gr.079558.108) PMID: [18550803](https://pubmed.ncbi.nlm.nih.gov/18550803/)
99. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods*. 2008 Jul; 5(7):621–8. doi: [10.1038/nmeth.1226](https://doi.org/10.1038/nmeth.1226) PMID: [18516045](https://pubmed.ncbi.nlm.nih.gov/18516045/)